Ryvu Therapeutics SA · GPW:RVU

Ryvu Therapeutics SA — Investor Presentation (March 2025)

48 slides from Ryvu Therapeutics SA's investor presentation, March 2025

  1. Slide 1: Corporate Presentation

    Slide 1: Corporate Presentation

    Developing therapeutics at the forefront of oncology Corporate Presentation March 2025

  2. Slide 2: Note on the presentation and forward-looking statements

    Slide 2: Note on the presentation and forward-looking statements

    Note on the presentation and forward-looking statements This document does not constitute a public offering in the meaning of the Regulation (EU) 2017/1129 of the European Parliament and of the Council, ​ or any other offer or invitation to acquire any Company's securities, nor the incentive to subm

  3. Slide 3: Ryvu is developing novel therapies to address high-value emerging targets in oncology

    Slide 3: Ryvu is developing novel therapies to address high-value emerging targets in oncology

    Ryvu is developing novel therapies to address high-value emerging targets in oncology​ Clinical and Prelinical Candidate Pipeline Novel Multi-Target Discovery RVU120 • First-in-class, oral CDK8/19 inhibitor​ • Four Ph II studies ongoing: mono and combo ONCO Prime Platform • Multiple novel precision

  4. Slide 4: Team with a strong track record of clinical development and shareholder value creation

    Slide 4: Team with a strong track record of clinical development and shareholder value creation

    Team with a strong track record of clinical development and shareholder value creation​ Pawel Przewięźlikowski, MSc, MBA Krzysztof Brzózka, PhD, MBA Hendrik Nogai, MD Kamil Sitarz, PhD, MBA CEO and Founder CSO CMO COO Vatnak Vat-Ho, MBA Jakub Janowski, MSc Justyna Żółtek, MSc Bartłomiej Konicki, MSc

  5. Slide 5: Broad pipeline addressing emerging targets in oncology

    Slide 5: Broad pipeline addressing emerging targets in oncology

    Broad pipeline addressing emerging targets in oncology EXPECTED PROGRAM INDICATION DISCOVERY PRECLINICAL PHASE I PHASE II PARTNER MILESTONES R/R AML Updated Ph II data in RIVER-81 (combo with venetoclax) 2Q25 Q R/R AML/HR-MDS RIVER-52 Updated Ph II data in RVU120 (monotherapy) (enrollment suspended)

  6. Slide 6: RVU120: First-in-Class CDK8/19 Inhibitor in Hematologic Malignancies

    Slide 6: RVU120: First-in-Class CDK8/19 Inhibitor in Hematologic Malignancies

    RVU120: First-in-Class CDK8/19 Inhibitor in Hematologic Malignancies

  7. Slide 7: RVU120 is a clinical-stage, first-in-class, small molecule CDK8/19 kinase inhibitor

    Slide 7: RVU120 is a clinical-stage, first-in-class, small molecule CDK8/19 kinase inhibitor

    RVU120 is a clinical-stage, first-in-class, small molecule CDK8/19 kinase inhibitor developed and fully-owned by Ryvu high selectivity 1 low risk of DDI (esp antifungals) easy to formulate orally bioavailable favorable safety profile RVU120 is an innovative dual CDK8/19 inhibitor designed to target

  8. Slide 8: RVU120: opportunities across a broad range of cancers

    Slide 8: RVU120: opportunities across a broad range of cancers

    RVU120: opportunities across a broad range of cancers Blood Cancers & Disorders Solid Tumors Medulloblastoma AML Low-risk MDS ACC Myelofibrosis (MF) Breast High-risk MDS MDS/MPN overlap syndrome Sarcoma NHL Diamond-Blackfan Anemia • Signs of clinical activity in AML  Translational evidence in multi

  9. Slide 9: RVU120 Diversified clinical program with high commercial potential

    Slide 9: RVU120 Diversified clinical program with high commercial potential

    RVU120 Diversified clinical program with high commercial potential 2024 2025 2026 2027 2028 Beyond 2028 I II III IV I II III IV I II III IV I II III IV I II III IV Phase II studies in hematologic malignancies • RIVER-81: AML, combination with venetoclax Ph II Part 1 Ph II Parts 2 and 3 Phase III (po

  10. Slide 10: RVU120 Phase II development plan rationale: RIVER-51 clinical data

    Slide 10: RVU120 Phase II development plan rationale: RIVER-51 clinical data

    RVU120 Phase II development plan rationale: RIVER-51 clinical data 15 of 30 evaluable patients showed clinical benefit across dose levels Clinical benefits • 30 treated patients are evaluable for response (38 were treated in total) • 9 patients achieved clinically significant BM blast reduction • (i

  11. Slide 11: Data generated in RIVER-51 study support further development of RVU120

    Slide 11: Data generated in RIVER-51 study support further development of RVU120

    Data generated in RIVER-51 study support further development of RVU120 in AML, LR-MDS and MF Significant blast reductions Transfusion independence Improvement of BM architecture • Confirmed CR in a patient with AML • >20% patients, (all with AML-MR or HR-MDS), • Signs of activity in secondary AML •

  12. Slide 12: RIVER-81 in ven-refractory patients with AML

    Slide 12: RIVER-81 in ven-refractory patients with AML

    Phase II study testing RVU120 in combination with venetoclax RIVER-81 in ven-refractory patients with AML STUDY DESIGN • Primary endpoints: ― Rate of CR, CRh, CRi, with and without MRD, and DoR • Secondary endpoints: Transfusion independence, PFS, RFS, OS RVU120 + • For Part 2: including PRO and HRQ

  13. Slide 13: RIVER-81 Strong nonclinical evidence for synergy between RVU120 and venetoclax

    Slide 13: RIVER-81 Strong nonclinical evidence for synergy between RVU120 and venetoclax

    RIVER-81 Strong nonclinical evidence for synergy between RVU120 and venetoclax providing rationale for a Phase II study in venetoclax refractory patients MV4-11 • True Synergy and Superiority: RVU120 + VEN • RVU120 + ven demonstrates synergy across multiple AML cell lines and superiority over ven +

  14. Slide 14: RIVER-81 Part 1 (dose escalation) has been completed

    Slide 14: RIVER-81 Part 1 (dose escalation) has been completed

    RIVER-81 Part 1 (dose escalation) has been completed; currently enrolling into Part 2 at the highest dose from Part 1 PART 1 PART 2: Simon 2-stage design PART 3: Confirmatory Stage 1 Stage 2 Confirmatory cohort Cohort 1 Cohort 2 Cohort 3 RVU120 125 mg RVU120 250 mg RVU120 250 mg RVU120 250 mg + N≤18

  15. Slide 15: RIVER-81 One patient achieved a CR in a difficult to treat ven-refractory population

    Slide 15: RIVER-81 One patient achieved a CR in a difficult to treat ven-refractory population

    RIVER-81 One patient achieved a CR in a difficult to treat ven-refractory population Data Cut-off: December 10, Preliminary data Decrease of bone marrow blasts from 20% to 9% in flow cytometry on C2D13 Cytomorphological decrease of bone marrow blasts to < 5% on C1D13 15

  16. Slide 16: POTAMI-61 Phase II study of RVU120 in myelofibrosis as mono and combo

    Slide 16: POTAMI-61 Phase II study of RVU120 in myelofibrosis as mono and combo

    POTAMI-61 Phase II study of RVU120 in myelofibrosis (MF) as mono and combo – first patient was dosed in December 2024 STUDY DESIGN • Population: • Primary or secondary MF; intermediate or high-risk MF per DIPSS; Cohort 1) previously treated with or ineligible for JAK inhibitor and Cohort 2) suboptim

  17. Slide 17: POTAMI-61 RVU120 validated preclinically as a drug candidate in MF

    Slide 17: POTAMI-61 RVU120 validated preclinically as a drug candidate in MF

    POTAMI-61 RVU120 validated preclinically as a drug candidate in MF Mechanism of RVU120 RVU120 reduces Opportunity in myelofibrosis in MF splenomegaly RVU120 as a monotherapy and in • Growing market with many patients undiagnosed or not treated combination with ruxolitinib reduces due to lack of trea

  18. Slide 18: REMARK and the EMSCO network

    Slide 18: REMARK and the EMSCO network

    RVU120 in LR-MDS – IIT conducted by Prof. Uwe Platzbecker REMARK and the EMSCO network STUDY DESIGN PHASE II • Population: • Patients with relapsed/refractory LR-MDS • Primary endpoint: EXPLORATORY • Erythroid response (HI-E) according to IWG 2018 criteria after 8 cycles of treatment RVU120 AS A SIN

  19. Slide 19: REMARK RVU120 validated preclinically as a drug candidate in LR-MDS

    Slide 19: REMARK RVU120 validated preclinically as a drug candidate in LR-MDS

    REMARK RVU120 validated preclinically as a drug candidate in LR-MDS Opportunity in LR-MDS Mechanism of RVU120 in LR-MDS • A high unmet medical need remains in low-risk MDS (LR-MDS) after failure of available therapies • Transfusion burden remains high for patients with LR-MDS, resulting a poor quali

  20. Slide 20: REMARK RVU120 strong erythroid-stimulating activity

    Slide 20: REMARK RVU120 strong erythroid-stimulating activity

    REMARK RVU120 has strong erythroid-stimulating activity in nonclinical anemia models and selected patients with AML/HR-MDS in Phase I (RIVER-51), providing the rationale for the Phase II clinical study in patients with LR-MDS Nonclinical rationale • Treatment of transformed CD34+ cells with RVU120 r

  21. Slide 21: RIVER-52 Phase II study with RVU120 as a single agent in AML/HR-MDS

    Slide 21: RIVER-52 Phase II study with RVU120 as a single agent in AML/HR-MDS

    RIVER-52 Phase II study with RVU120 as a single agent in AML/HR-MDS STUDY DESIGN • Primary endpoints: ― Rate of CR, CRh, CRi, with and without MRD, and DoR RVU120 • Secondary endpoints: monotherapy ― Transfusion independence, Progression-free survival, Relapse-free survival (RFS), Overall survival •

  22. Slide 22: RVU120 Phase II clinical development with a global footprint

    Slide 22: RVU120 Phase II clinical development with a global footprint

    RVU120 Phase II clinical development with a global footprint Global site locations and patient population Global CROs and clinical vendors Planned locations for RVU120 Ph II studies: Part 1: exploratory data Regulatory authorities Part 2: expansion worldwide Status as of February 24, 2025 Number of

  23. Slide 23: RVU120 Market potential in hematological malignancies

    Slide 23: RVU120 Market potential in hematological malignancies

    RVU120 Market potential in hematological malignancies AML (Acute Myeloid Leukemia) MDS (Myelodysplastic Syndrome) MF (Myelofibrosis) • The most common, highly aggressive type • Disease leading to bone marrow damage, • MF is a bone marrow disease characterized of acute leukemia occurring in adults; c

  24. Slide 24: Program on track with next efficacy readouts in Q2 2025

    Slide 24: Program on track with next efficacy readouts in Q2 2025

    Program on track with next efficacy readouts in Q2 2025 RVU120 Approx. 120 patients have already been dosed across all RVU120 Phase II studies RVU120 program summary • Accelerating enrollment across Phase II program RIVER-81 Next data in Q2 2025 o 3 Phase II studies in progress as planned: • Part 1

  25. Slide 25: Dapolsertib (MEN1703, SEL24) First-in-Class PIM/FLT3 Inhibitor

    Slide 25: Dapolsertib (MEN1703, SEL24) First-in-Class PIM/FLT3 Inhibitor

    Dapolsertib (MEN1703, SEL24) First-in-Class PIM/FLT3 Inhibitor

  26. Slide 26: Dapolsertib JASPIS-01 Phase II clinical study in DLBCL

    Slide 26: Dapolsertib JASPIS-01 Phase II clinical study in DLBCL

    Dapolsertib (MEN1703, SEL24) JASPIS-01 Phase II clinical study in DLBCL DLBCL PARTNERSHIP AGREEMENT PROVEN SAFETY WITH MENARINI GROUP AND CLINICAL ACTIVITY • Development to continue with the initiation of a new Phase II study in relapsed/refractory diffuse large B-cell (2017) lymphoma (DLBCL) Future

  27. Slide 27: Initiating Phase II in DLBCL

    Slide 27: Initiating Phase II in DLBCL

    Initiating Phase II in DLBCL DAPOLSERTIB PROFILE • First-in-class dual PIM/FLT3 inhibitor with a unique mechanism of action • Differentiated activity in cellular models compared to selective PIM inhibitors (broader activity profile) CLINICAL STUDIES TO DATE • H1 2017- H1 2021 Phase I dose escalation

  28. Slide 28: RVU305: Differentiated PRMT5 inhibitor

    Slide 28: RVU305: Differentiated PRMT5 inhibitor

    RVU305: Differentiated PRMT5 inhibitor

  29. Slide 29: RVU305: Best-in-class PRMT5 MTA-cooperative inhibitor in IND-enabling studies

    Slide 29: RVU305: Best-in-class PRMT5 MTA-cooperative inhibitor in IND-enabling studies

    RVU305: Best-in-class PRMT5 MTA-cooperative inhibitor in IND-enabling studies RVU305/PRMT5i RVU305 has best-in-class potential based on robust multiparameter optimization​ PRMT5 MTA-cooperative inhibitors • Antiproliferative activity demonstrated in MTAP- KEY RATIONALE exert synthetic lethal phenoty

  30. Slide 30: RVU305 shows superiority in multiple cell lines

    Slide 30: RVU305 shows superiority in multiple cell lines

    RVU305 shows superiority in multiple cell lines Analysis of pancreatic, lung and bladder cancer origin cell lines shows RVU305 superiority over MRTX1719 • Panel of MTAP-deleted and MTAP-wt cells was profiled with RVU305 in a 5-day CellTiter-Glo assay • A differential response to Ryvu PRMT5 MTA-coope

  31. Slide 31: Favorable PK profile for RVU305 is promising for clinical development

    Slide 31: Favorable PK profile for RVU305 is promising for clinical development

    Favorable PK profile for RVU305 is promising for clinical development RVU305 shows improved exposure and target coverage compared to MRTX1719. The murine pharmacokinetic profile and exposure at pharmacologically relevant doses—75 mg/kg BID for RVU305 and 100 mg/kg QD for MRTX1719 – indicates that RV

  32. Slide 32: RVU305 shows significant antitumor efficacy in vivo

    Slide 32: RVU305 shows significant antitumor efficacy in vivo

    RVU305 shows significant antitumor efficacy in vivo Strong antitumor efficacy Complete responses demonstrated in vivo: favorable vs. MRTX1719 DoHH2 MTAP-deleted model (DLBCL) Tumor volume Tumor volume Tumor volume 4096 Individual tumor volume [mm3] 4096 RVU305, 150 mg/kg PO QD 4096 Individual tumor

  33. Slide 33: RVU305 has best-in-class potential vs. clinical competitors

    Slide 33: RVU305 has best-in-class potential vs. clinical competitors

    RVU305 has best-in-class potential vs. clinical competitors MRTX1719 TNG908 TNG462 AMG193 RVU305 Potency 1 +++ + +++ ++ +++ Viability fold shift MTAP KO/MTAP WT +++ + ++ ++ ++++ Residence time +++ + ND ND +++ % of highly sensitive MTAP deleted cell lines 36% ND ND ND 63% in Omniscreen2 Brain penetra

  34. Slide 34: ONCO Prime: Novel Precision Oncology

    Slide 34: ONCO Prime: Novel Precision Oncology

    ONCO Prime: Novel Precision Oncology Multi-asset platform generating first-in-class therapeutics

  35. Slide 35: Driving novel precision oncology drug discovery with Ryvu's ONCO Prime platform

    Slide 35: Driving novel precision oncology drug discovery with Ryvu's ONCO Prime platform

    Driving novel precision oncology drug discovery with Ryvu’s ONCO Prime platform Discovering Novel Precision Oncology Ryvu’s CRISPR-based target Discovery Platform Targets, including Synthetic Lethal Targets Engineered Model Patient-Derived Cells (PDCs) Synthetic Common APC KRAS TP53 SMAD4 essential

  36. Slide 36: Initial ONCO Prime data presented in CRC

    Slide 36: Initial ONCO Prime data presented in CRC

    Initial ONCO Prime data presented in CRC; broad applicability across oncology • The third most prevalent cancer worldwide • Estimated number of colorectal cancers in the US for 2024 are 153,000 new cases1 CRC • Diagnosed usually at an advanced stage. Mortality still remains high. Five-year survival

  37. Slide 37: ONCO Prime is accelerating the development of novel precision medicine targets

    Slide 37: ONCO Prime is accelerating the development of novel precision medicine targets

    ONCO Prime is accelerating the development of novel precision medicine targets, including synthetic lethal targets Modeling cancer progression High Throughput Screenings Novel Targets & Treatments APC KRAS TP53 SMAD4 Patient-derived material Ryvu’s OncoPrime platform has broad potential to discover

  38. Slide 38: ADCs with Novel Payloads

    Slide 38: ADCs with Novel Payloads

    ADCs with Novel Payloads Generating multiple first-in-class therapeutics

  39. Slide 39: Novel payloads have the potential to improve efficacy and safety in next generation ADCs

    Slide 39: Novel payloads have the potential to improve efficacy and safety in next generation ADCs

    Novel payloads have the potential to improve efficacy and safety in next generation ADCs Approved ADCs use three main types of payloads Novel payloads have the potential to improve on… Efficacy: overcome resistance to existing payloads and potentially improve on potency Safety: expand the safety win

  40. Slide 40: Ryvu's payload strategy is focused on novel and potent mechanisms

    Slide 40: Ryvu's payload strategy is focused on novel and potent mechanisms

    ADCs Ryvu’s payload strategy is focused on novel and potent mechanisms PAYLOAD CLASSES IMMUNOMODULATORY SYNTHETICALLY LETHAL/ IMMUNOCYTOTOXIC POTENT CYTOTOXINS PAYLOADS PRECISION PAYLOADS PAYLOADS Traditional approach A newer approach Innovative approach Innovative approach Established cytotoxics •

  41. Slide 41: Ryvu has shortlisted several immunocytotoxic payloads to advance

    Slide 41: Ryvu has shortlisted several immunocytotoxic payloads to advance

    Ryvu has shortlisted several immunocytotoxic payloads to advance Based on initial screens at Ryvu, several targets have been selected as promising immunocytotoxic payloads. Some blinded examples are presented below. Low nM PoC as Single agent Pantoxic IO combo Target Drug name inhibitors ADC Type of

  42. Slide 42: STING agonists licensed to Exelixis for ADCs

    Slide 42: STING agonists licensed to Exelixis for ADCs

    Ryvu has already developed a portfolio of immunostimulatory payloads: STING agonists licensed to Exelixis for ADCs 1 Building STING-based antibody drug conjugates (ADCs) 2 Leveraging Ryvu’s STING agonist portfolio and Exelixis’s ADC technology Partnership Key Financial Terms • Exclusive license agre

  43. Slide 43: BioNTech and Ryvu: global collaboration on immune modulation small molecules

    Slide 43: BioNTech and Ryvu: global collaboration on immune modulation small molecules

    BioNTech and Ryvu: global collaboration to develop and commercialize immune modulation small molecule candidates Largest-ever Ryvu deal: November 2022 Partnership Key Financial Terms • Multi-target research collaboration: Ryvu is conducting • Ryvu received €40 million from BioNTech, discovery and re

  44. Slide 44: Corporate Progress

    Slide 44: Corporate Progress

    ”n n cD) pes OO oO pes a. cD) ~~ Oo es oO [ok S oO O RY¥U

  45. Slide 45: Full-Year Financial Results: 2024

    Slide 45: Full-Year Financial Results: 2024

    Full-Year Financial Results: 2024 € million 2023* 2024* Revenues 15.0 23.7 Cash position March 9, 2025 Partnering 10.5 18.1 Grants 4.5 5.6 €43.7M (PLN 182.3M) Total Costs** 34.7 51.0 In addition, the company has secured approximately Clinical Pipeline 12.0 25.7 €21.8M (PLN 91.0M) in non-dilutive gra

  46. Slide 46: 2025 Key Goals and Financing

    Slide 46: 2025 Key Goals and Financing

    Ryvu’s Vision: from 2026, Ryvu will improve the lives of cancer patients worldwide 2025 KEY GOALS AND FINANCING • Research funding from existing R&D collaborations • Milestones from existing R&D collaborations • RVU120 broad development • New grant funding (including potential fast-to-market strateg

  47. Slide 47: Ryvu equity summary

    Slide 47: Ryvu equity summary

    Ryvu equity summary Top Holders3 IPO on WSE Nov 2014 1 Paweł Przewięźlikowski 17.4% Corporate Split: Selvita and Ryvu Oct 2019 2 Allianz TFI 9.9% Ticker: WSE RVU 3 Allianz OFE 9.2% 4 BioNTech SE 8.3% 52-Week Range1 PLN 17.62 – 59.40 5 Nationale-Nederlanden OFE 7.9% Average Daily Volume (YTD) 1 34,26

  48. Slide 48: Thank you

    Slide 48: Thank you

    Thank you CONTACT DATA: Ryvu Therapeutics S.A. www.ryvu.com ryvu@ryvu.com ir@ryvu.com

Source: Internet Archive copy of ryvu.com

More decks from Ryvu Therapeutics SA

All 21 Ryvu Therapeutics SA decks